About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Microbiology research group of the Vall d'Hebron Research Institute (VHIR) focuses on the study of microbiological aspects —in basic, translational and clinical research— that could improve the outcome of patients with infectious diseases.
Our priority research areas are:
We actively collaborate with other microbiology laboratories, health services, national and international centres and organizations, as well as with the different research networks of the Carlos III Health Institute in Spain.
In addition, we carry out an important activity in the surveillance of the genotypic and phenotypic evolution of microorganisms present in the community in terms of their virulence, transmissibility, antigenic escape and antimicrobial resistance, in collaboration with public administrations, both at the national and international level.
PMID: 32055721 Journal: Parasite epidemiology and control Year: 2020 Reference: Parasite Epidemiol Control. 2020 Jan 10;9:e00137. doi: 10.1016/j.parepi.2020.e00137. eCollection 2020 May. Impact factor: 0 Publication type: Paper in international publication Authors: Not, Anna, Salvador, Fernando, Goterris, Lidia, Sulleiro, Elena, Lopez, Isabel, Balladares, Martha, Garcia, Elena, Paz, Carmen, Sanchez-Montalva, Adrian, Bosch-Nicolau, Pau et al. DOI: 10.1016/j.parepi.2020.e00137
PMID: 31843689 Journal: JOURNAL OF INFECTION Year: 2020 Reference: J Infect. 2020 Feb;80(2):190-196. doi: 10.1016/j.jinf.2019.12.006. Epub 2019 Dec 13. Impact factor: 4.842 Publication type: Paper in international publication Authors: Ferrer, Ricard, Nuvials, Xavier, Deu, Maria, Peghin, Maddalena, Gonzalez-Lopez, Juan Jose, Lung, Mayli, Roman, Antonio, Gavalda, Joan, Len, Oscar, Berastegui, Cristina et al. DOI: 10.1016/j.jinf.2019.12.006
PMID: 32020041 Journal: Scientific Reports Year: 2020 Reference: Sci Rep. 2020 Feb 4;10(1):1760. doi: 10.1038/s41598-020-58691-3. Impact factor: 3.998 Publication type: Paper in international publication Authors: Aregall, Nuria, Michl, Kristina, Sabria, Jaume, Rodriguez Garrido, Virginia, Goterris, Lidia, Bosch, Albert, Pinto, Rosa Maria, Guix, Susana, Sabria, Aurora, Vu, Diem-Lan et al. DOI: 10.1038/s41598-020-58691-3
PMID: 31830370 Journal: Small Year: 2020 Reference: Small. 2020 Jan;16(3):e1906108. doi: 10.1002/smll.201906108. Epub 2019 Dec 12. Impact factor: 11.459 Publication type: Paper in international publication Authors: Ferrer, Ricard, Fabrega, Anna, Altug, Hatice, Ruiz-Rodriguez, Juan Carlos, Gonzalez-Lopez, Juan Jose, Yesilkoy, Filiz, Belushkin, Alexander et al. DOI: 10.1002/smll.201906108
PMID: 30717741 Journal: BMC PUBLIC HEALTH Year: 2019 Reference: BMC Public Health. 2019 Feb 4;19(1):144. doi: 10.1186/s12889-019-6448-3. Impact factor: 2.567 Publication type: Paper in international publication Authors: Santoma, Maria Jose, Gorrindo, Pilar, Palau, Pilar, Cunille, Montse, Masdeu, Eva, Avellanes, Ingrid, Rodrigo, Jose Angel, Codina, Gema, Martin, Maria Teresa, Gonzalez, Juan Jose et al. DOI: 10.1186/s12889-019-6448-3
PMID: 30587519 Journal: NEUROLOGY Year: 2019 Reference: Neurology. 2019 Feb 5;92(6):296-298. doi: 10.1212/WNL.0000000000006801. Epub 2018 Dec 26. Impact factor: 8.689 Publication type: Paper in international publication Authors: Pappolla, Agustin, Midaglia, Luciana, Boix Rodriguez, Claudia P, Puig, Adaia Albasanz, Lung, Maiylyi, Camps, Isabel Ruiz, Castillo, Joaquin, Mulero, Patricia, Arrambide, Georgina, Rodriguez-Acevedo, Breogan et al. DOI: 10.1212/WNL.0000000000006801
PMID: 30315920 Journal: INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS Year: 2019 Reference: Int J Antimicrob Agents. 2019 Feb;53(2):165-170. doi: 10.1016/j.ijantimicag.2018.10.003. Epub 2018 Oct 10. Impact factor: 4.615 Publication type: Paper in international publication Authors: Almirante, Benito, Bartolome, Rosa, Gonzalez-Lopez, Juan Jose, Pigrau, Carlos, Rodriguez-Pardo, Dolors, Escola-Verge, Laura, Fernandez-Hidalgo, Nuria et al. DOI: 10.1016/j.ijantimicag.2018.10.003
PMID: 30100098 Journal: ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA Year: 2019 Reference: Enferm Infecc Microbiol Clin. 2019 Feb;37(2):145-146. doi: 10.1016/j.eimc.2018.07.004. Epub 2018 Aug 9. Impact factor: 1.685 Publication type: Letter or abstract Authors: Serra-Pladevall, Judit, Espasa, Mateu, Andreu, Antonia, Barbera, Maria-Jesus et al. DOI: 10.1016/j.eimc.2018.07.004
The new diagnostic method, designed for use in endemic regions, combines a mobile application with a low-cost robotic microscope.
The European network EUPertStrain celebrates its annual meeting, focused on the study of the evolution of Bordetella pertussis, the bacterium responsible for this disease that can be very serious in children under one year.
The Vall d'Hebron work has shown that people vaccinated with Pfizer or Moderna have specific memory T lymphocytes against SARS-CoV-2 in the lung months after vaccination.
